Detalles de la búsqueda
1.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
2.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739404
3.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
4.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107329
5.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine
; 60: 102016, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396800
6.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396807
7.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666982
8.
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
J Clin Oncol
; 40(29): 3406-3418, 2022 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605179
9.
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Blood Cancer J
; 11(6): 106, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083504
10.
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients.
Clin Cancer Res
; 27(13): 3695-3703, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926915
11.
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.
Clin Cancer Res
; 26(18): 4832-4841, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32616499
12.
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.
Blood Cancer J
; 11(4): 73, 2021 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33846296
13.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer J
; 11(12): 197, 2021 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34876566
14.
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Blood Cancer J
; 10(5): 58, 2020 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424154
Resultados
1 -
14
de 14
1
Próxima >
>>